Ludwig Institute for Cancer Research Limited

Massachusetts Institute of Technology

Commonwealth Scientific and Industrial Research Organisation

Beijing University of Technology

University of California

Memorial Sloan Kettering Cancer Center

Telstra Corporation Limited

Kalobios Pharmaceuticals, Inc.

Paracrine Therapeutics Ab

Andrew Ewart Scott

Antony Wilks Burgess

Terrance Grant Johns

Lloyd J Old

Christoph Renner

K Dane Wittrup

Timothy Edward Adams

Martin Lackmann

Peter Anthony Hoyne

Ginger Chao

Christopher Robert Bebbington

Ulf Eriksson

Geoffrey T Yarranton

Webster K Cavenee

Elizabeth Stockert

Dimitar B Nikolov

Frank Furnari

Nayanendu Saha

Peter W Janes

Hong Li

Douglas Gavin Currie

David William Maxwell Reekie

Lakmali Atapattu Mudiyanselage

James Edward Broughton

Phillip John Rennie Pearl

Peter Scott Black

Veronika M Rayzman

Carmelina Murone

Catherine To

Laura Allan

The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.

Methods and compositions for PDGF-CC inhibition

Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.

Anti-metalloprotease antibody for diagnosis and treatment of cancers

The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof

A system includes a rejection module in a phone configured to receive calls over a network and a remote rejection announcement server (RAS) configured to receive calls over the network. The rejection module is configured to generate at least a portion of an incoming call user interface (UI) on the phone. The UI indicates incoming call signalling, associated with an incoming call from a caller, over a call signalling path in the network. One or more rejection options is provided for selection by a caller. Rejection reason data is generated based on selecting one of the rejection options. The rejection reason data is sent using a rejection reason path separate from the call signalling path. The remote RAS is configured to receive the incoming call from the caller, receive the rejection reason data over the rejection reason path, and generate an audio/video message based on the rejection reason data.

Callee rejection information for rejected voice calls

The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.

Treatment method using EGFR antibodies and SRC inhibitors and related formulations

The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.

Antibodies to EGF receptor epitope peptides and uses thereof

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.

EphA3 antibodies for the treatment of solid tumors

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Humanized GM-CSF antibodies

Antibodies to EGF receptor epitope peptides

Fusion proteins of humanized g250 specific antibodies and uses thereof

Chimerized GM-CSF antibodies

Growing community of inventors

Melbourne, Australia

Andrew Ewart Scott